BiotechTube
Kodiak Sciences

Kodiak Sciences

KOD
Palo Alto, United States· Est. 2009

Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.

kodiak.com

KOD · Stock Price

USD 21.85+18.84 (+625.91%)
Market Cap: $1.4B

Historical price data

AI Company Overview

Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.

OphthalmologyRetinal Diseases

Technology Platform

The Antibody Biopolymer Conjugate Drug (ABCD) Platform conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life for durability and enables high drug-antibody ratios for multi-mechanistic therapies.

Pipeline

11
11 drugs in pipeline10 in Phase 3
DrugIndicationStageWatch
KSI-301 + AfliberceptWet Age-related Macular DegenerationPhase 3
KSI-301 + AfliberceptDiabetic Macular EdemaPhase 3
KSI-301Non-proliferative Diabetic RetinopathyPhase 3
TarcocimabDiabetic RetinopathyPhase 3
Tarcocimab tedromer + Tabirafusp tedromer + AfliberceptWet Age-related Macular DegenerationPhase 3

Funding History

4
Total raised:$525M
PIPE$225MDec 15, 2020
IPO$150MOct 18, 2018
Series B$100MJan 15, 2018
Series A$50MJan 15, 2015

Opportunities

The primary growth opportunity lies in successfully commercializing tarcocimab as a durable anti-VEGF therapy, capturing market share in multi-billion dollar retinal disease markets.
Further upside exists in expanding the ABCD platform to develop multi-mechanistic bispecifics (KSI-501, KSI-101) that address inflammation and angiogenesis, potentially opening new treatment paradigms and patient segments.

Risk Factors

Key risks include clinical trial failures or safety issues with lead candidate tarcocimab, intense competition from established and next-generation anti-VEGF therapies, and the challenge of commercializing a novel therapy in a crowded market.
The company also faces execution risk in scaling its proprietary manufacturing and depends on continued access to capital.

Competitive Landscape

Kodiak competes directly with major players like Regeneron (Eylea), Roche (Vabysmo, Lucentis), and Novartis (Beovu) in the anti-VEGF space. Its main differentiation is the designed-in durability of its ABCD platform, aiming for less frequent dosing than current standards, and its pipeline of bispecific candidates that target both VEGF and inflammatory pathways like IL-6.